Azeliragon

N/A

Report date: 2024/10/18 09:47:44
NME

Base Information

Drug NameAzeliragon
Drug Alias Nameazeliragonum阿齐瑞格阿折立冈PF-4494700PF-04494700 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdvanced glycosylation end product-specific receptor antagonists
TargetsAdvanced glycosylation end product-specific receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Brain metastasesDiabetic Nephropathies +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesVtv Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesGeorgetown UniversityWashington University School Of MedicineUniversity Of Texas Medical Branch +[4] 
Inactive CompaniesVtv TherapeuticsPfizer IncNational Cancer Institute
Active IndicationsCoronavirus Disease 2019 (COVID-19)Brain metastasesNeoplasm Metastasis +[6] 
Inactive IndicationsDiabetic NephropathiesAlzheimer DiseaseGlioma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A